Top Markets
Coin of the day
Tvardi Therapeutics, Inc. Tvardi Therapeutics, Inc.

Tvardi Therapeutics, Inc.

TVRD
Clasificación en acciones #30251
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages... Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
Precio por acción
$1.88
Última sincronización: 2026-08-18
Capitalización bursátil
$17.59M
Cambio (1 día)
0.81%
Cambio (1 año)
-92.40%
País
US
Comercio Tvardi Therapeutics, Inc. (TVRD)

Categoría

Historial de rendimiento por dividendo de Tvardi Therapeutics, Inc. (TVRD)
Rendimiento por dividendo (TTM) de Tvardi Therapeutics, Inc. (símbolo bursátil: TVRD) al 2026: 0
Rendimiento promedio por dividendo de los últimos 5 años: 0.00%
Historial de rendimiento por dividendo de Tvardi Therapeutics, Inc. (TVRD) desde 2026 hasta 2026
Rendimiento por dividendo al final de cada año (TTM)
Año Rendimiento por dividendo Cambiar
Not enough data for the provided dates.
Rendimientos por dividendo (TTM) de empresas similares o competidoras
Empresa Rendimiento por dividendo País
0.00%
US
0.00%
NL
3.12%
AU
0.00%
CH
0.48%
BE